View Item 

Show simple item record

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
dc.contributor.authorBan‐hoefen, Makikoen_US
dc.contributor.authorVanderplas, Annen_US
dc.contributor.authorCrosby‐thompson, Allison L.en_US
dc.contributor.authorAbel, Gregory A.en_US
dc.contributor.authorCzuczman, Myron S.en_US
dc.contributor.authorGordon, Leo I.en_US
dc.contributor.authorKaminski, Mark S.en_US
dc.contributor.authorKelly, Jenniferen_US
dc.contributor.authorMillenson, Michaelen_US
dc.contributor.authorNademanee, Auayporn P.en_US
dc.contributor.authorRodriguez, Maria A.en_US
dc.contributor.authorZelenetz, Andrew D.en_US
dc.contributor.authorNiland, Joyceen_US
dc.contributor.authorLaCasce, Ann S.en_US
dc.contributor.authorFriedberg, Jonathan W.en_US
dc.date.accessioned2013-11-01T19:00:58Z
dc.date.available2015-01-05T13:54:45Zen_US
dc.date.issued2013-11en_US
dc.identifier.citationBan‐hoefen, Makiko ; Vanderplas, Ann; Crosby‐thompson, Allison L. ; Abel, Gregory A.; Czuczman, Myron S.; Gordon, Leo I.; Kaminski, Mark S.; Kelly, Jennifer; Millenson, Michael; Nademanee, Auayporn P.; Rodriguez, Maria A.; Zelenetz, Andrew D.; Niland, Joyce; LaCasce, Ann S.; Friedberg, Jonathan W. (2013). "Transformed nonâ Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database." British Journal of Haematology 163(4): 487-495.en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100290
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherStem‐Cell Transplantationen_US
dc.subject.otherDiffuse Large B‐Cell Lymphomaen_US
dc.subject.otherNon‐Hodgkin Lymphomaen_US
dc.subject.otherRituximab Eraen_US
dc.subject.otherHistological Transformationen_US
dc.titleTransformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes databaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100290/1/bjh12570.pdf
dc.identifier.doi10.1111/bjh.12570en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceLaCasce, A.S., Kho, M.E., Friedberg, J.W., Niland, J.C., Abel, G.A., Rodriguez, M.A., Czuczman, M.S., Millenson, M.M., Zelenetz, A.D. & Weeks, J.C. ( 2008 ) Comparison of Referring and Final Pathology for Patients with Non‐Hodgkin's Lymphoma in the National Comprehensive Cancer Network. Journal of Clinical Oncology, 26, 5107 – 5112.en_US
dc.identifier.citedreferenceBains, P., Al‐Tourah, A., Campbell, B.A., Pickles, T., Gascoyne, R.D., Connors, J.M. & Savage, K.J. ( 2013 ) Incidence of transformation to aggressive lymphoma in limited‐stage follicular lymphoma treated with radiotherapy. Annals of Oncology, 24, 428 – 432.en_US
dc.identifier.citedreferenceBastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G., Dumontet, C., Bryon, P.A. & Coiffier, B. ( 1997 ) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. Journal of Clinical Oncology, 15, 1587 – 1594.en_US
dc.identifier.citedreferenceBernstein, S.H. & Burack, W.R. ( 2009 ) The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program, 2009, 532 – 541.en_US
dc.identifier.citedreferenceCarlotti, E., Wrench, D., Matthews, J., Iqbal, S., Davies, A., Norton, A., Hart, J., Lai, R., Montoto, S., Gribben, J.G., Lister, T.A. & Fitzgibbon, J. ( 2009 ) Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the Follicular Lymphoma clone. Blood, 113, 3553 – 3557.en_US
dc.identifier.citedreferenceChen, C.I., Crump, M., Tsang, R., Stewart, A.K. & Keating, A. ( 2001 ) Autotransplants for histologically transformed follicular non‐Hodgkin's lymphoma. British Journal of Haematology, 113, 202 – 208.en_US
dc.identifier.citedreferenceCzuczman, M.S., Vose, J.M., Witzig, T.E., Zinzani, P.L., Buckstein, R., Polikoff, J., Li, J., Pietronigro, D., Ervin‐Haynes, A. & Reeder, C.B. ( 2011 ) The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin. British Journal of Haematology, 154, 477 – 481.en_US
dc.identifier.citedreferenceDavies, A.J., Rosenwald, A., Wright, G., Lee, A., Last, K.W., Weisenburger, D.D., Chan, W.C., Delabie, J., Braziel, R.M., Campo, E., Gascoyne, R.D., Jaffe, E.S., Muller‐Hermelink, K., Ott, G., Calaminici, M., Norton, A.J., Goff, L.K., Fitzgibbon, J., Staudt, L.M. & Lister, A.T. ( 2007 ) Transformation of follicular lymphoma to diffuse large B cell lymphoma proceeds by distinct oncogenic mechanisms. British Journal of Haematology, 136, 286 – 293.en_US
dc.identifier.citedreferenceDoocey, R.T., Toze, C.L., Connors, J.M., Nevill, T.J., Gascoyne, R.D., Barnett, M.J., Forrest, D.L., Hogge, D.E., Lavoie, J.C., Nantel, S.H., Shepherd, J.D., Sutherland, H.J., Voss, N.J., Smith, C.A. & Song, K.W. ( 2005 ) Allogeneic hematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma. British Journal of Haematology, 131, 223 – 230.en_US
dc.identifier.citedreferenceEide, M.B., Lauritzsen, G.F., Kvalheim, G., Kolstad, A., Fagerli, U.M., Maisenholder, M., Ostenstad, B., Fluge, O., Delabie, J., Aarset, H., Liestol, K. & Holte, H. ( 2011 ) High dose chemotherapy with autologous stem cell support for patients with histologically transformed B‐cell non‐Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology, 152, 600 – 610.en_US
dc.identifier.citedreferenceFisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. ( 2005a ) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 8447 – 8452.en_US
dc.identifier.citedreferenceFisher, R.I., Kaminski, M.S., Wahl, R.L., Knox, S.J., Zelenetz, A.D., Vose, J.M., Leonard, J.P., Kroll, S., Goldsmith, S.J. & Coleman, M. ( 2005b ) Tositumomab and iodine‐131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low‐grade and transformed non‐Hodgkin's lymphomas. Journal of Clinical Oncology, 23, 7565 – 7573.en_US
dc.identifier.citedreferenceForan, J.M., Apostolidis, J., Papamichael, D., Norton, A.J., Matthews, J., Amess, J.A., Lister, T.A. & Rohatiner, A.Z. ( 1998 ) High‐dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Annals of Oncology, 9, 865 – 964.en_US
dc.identifier.citedreferenceFriedberg, J. ( 2012 ) Double hit diffuse large B cell lymphoma. Journal of Clinical Oncology, 30, 3439 – 3443.en_US
dc.identifier.citedreferenceFriedberg, J.W., Neuberg, D., Gribben, J.G., Mauch, P., Anderson, K.C., Soiffer, R.J., Takvorian, T., Fisher, D.C., Schlossman, R., Jallow, H., Kuhlman, C., Ritz, J. & Freedman, A.S. ( 1999 ) Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biology of Blood and Bone Marrow Transplantation, 5, 262 – 268.en_US
dc.identifier.citedreferenceWondergem, M.J., Zijlstra, J.M., de Rooij, M., Visser, O.J., Huijgens, P.C. & Zweegman, S. ( 2012 ) Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan‐BEAM and autologous stem cell transplantation. British Journal of Haematology, 157, 395 – 397.en_US
dc.identifier.citedreferenceGisselbrecht, C., Glass, B., Mounier, N., Singh, G.D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Briere, J., Moskowitz, C.H. & Schmitz, N. ( 2010 ) Salvage regimens with autologous transplantation for relapsed large B‐cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 4184 – 4190.en_US
dc.identifier.citedreferenceGlas, A.M., Knoops, L., Delahaye, L., Kersten, M.J., Kibbelaar, R.E., Wessels, L.A., van Laar, R., van Krieken, J.H., Baars, J.W., Raemaekers, J., Kluin, P.M. & van't Veer, L.J. & de John, D. ( 2007 ) Gene‐expression and immunohistochemical study of specific T‐cell subsets and accessory cell types in the transformation and prognosis of Follicular Lymphoma. Journal of Clinical Oncology, 25, 390 – 398.en_US
dc.identifier.citedreferenceGordon, L.I., Witzig, T., Molina, A., Czuczman, M., Emmanouilides, C., Joyce, R., Vo, K., Theuer, C., Pohlman, B., Bartlett, N., Wiseman, G., Darif, M. & White, C. ( 2004 ) Yttrium 90‐labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B‐cell lymphoma. Clinical Lymphoma, 5, 98 – 101.en_US
dc.identifier.citedreferenceLawrie, C.H., Chi, J., Taylor, S., Tramonti, D., Ballabio, E., Palazzo, S., Saunders, N.J., Pezzella, F., Boultwood, J., Wainscoat, J.S. & Hatton, C.S. ( 2009 ) Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. Journal of Cellular and Molecular Medicine, 13, 1248 – 1260.en_US
dc.identifier.citedreferenceLink, B.K., Maurer, M.J., Nowakowski, G.S., Ansell, S.M., Macon, W.R., Syrbu, S.I., Slager, S.L., Thompson, C.A., Inwards, D.J., Johnston, P.B., Colgan, J.P., Witzig, T.E., Habermann, T.M. & Cerhan, J.R. ( 2012 ) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology, 26, 3272 – 3278.en_US
dc.identifier.citedreferenceMartinez‐Climent, J.A., Alizadeh, A.A., Segraves, R., Blesa, D., Rubio‐Moscardo, F., Albertson, D.G., Garcia‐Conde, J., Dyer, M.J., Levy, R., Pinkel, D. & Lossos, I.S. ( 2003 ) Transformation of follicular lymphoma to diffuse large B cell lymphoma is associated with heterogeneous set of DNA copy number and gene expression alterations. Blood, 101, 3109 – 3117.en_US
dc.identifier.citedreferenceMontoto, S., Davies, A.J., Matthews, J., Calaminici, M., Norton, A.J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A.Z. & Lister, T.A. ( 2007 ) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B‐cell lymphoma. Journal of Clinical Oncology, 25, 2426 – 2433.en_US
dc.identifier.citedreferenceRamadan, K.M., Connors, J.M. & Al‐Tourah, A. ( 2008 ) Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma [abstract]. Blood, 112, 4459.en_US
dc.identifier.citedreferenceReddy, N., Oluwole, O., Greer, J.P., Goodman, S., Engelhardt, B., Jagasia, M.H. & Savani, B.N. ( 2012 ) Superior long‐term outcome of patients with early transformation of non‐Hodgkin lymphoma undergoing stem cell transplantation. Clinical Lymphoma, Myeloma, and Leukemia, 12, 406 – 411.en_US
dc.identifier.citedreferenceRezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R. & Maloney, D.G. ( 2008 ) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non‐Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 211 – 217.en_US
dc.identifier.citedreferenceRossi, D., Berra, E., Cerri, M., Deambrogi, C., Barbieri, C., Franceschetti, S., Lunghi, M., Conconi, A., Paulli, M., Matolcsy, A., Pasqualucci, L., Capello, D. & Gaidano, G. ( 2006 ) Aberrant somatic hypermutation in transformation of follicular lymphoma and CLL to diffuse large B cell lymphoma. Haematologica, 91, 1405 – 1409.en_US
dc.identifier.citedreferenceSabloff, M., Atkins, H.L., Bence‐Bruckler, I., Bredeson, C., Fergusson, D., Genest, P., Hopkins, H., Hutton, B., Mcdiarmid, S. & Huebsch, L.B. ( 2007 ) A 15‐year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biology of Blood and Marrow Transplantation, 13, 956 – 964.en_US
dc.identifier.citedreferenceSwenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman‐Hoffman, V.L., Chrischilles, E. & Link, B.K. ( 2005 ) Improved survival of follicular lymphoma patients in the United States. Journal of Clinical Oncology, 23, 5019 – 5026.en_US
dc.identifier.citedreferenceThomson, K.J., Morris, E.C., Bloor, A., Cook, G., Milligan, D., Parker, A., Clark, F., Yung, L., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. ( 2009 ) Favorable long‐term survival after reduced‐intensity allogeneic transplantation for multiple‐relapse aggressive non‐Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 426 – 432.en_US
dc.identifier.citedreferenceVilla, D., Crump, M., Panzarella, T., Savage, K.J., Toze, C.L., Stewart, D.A., MacDonald, D.A., Buckstein, R., Lee, C., Alzahrani, M., Rubinger, M., Foley, R., Xenocostas, A., Sabloff, M., Muccilli, Al., Chua, N., Couture, F., Larouche, J.F., Cohen, S., Connors, J.M., Ambler, K., Al‐Tourah, A., Ramadan, K.M. & Kuruvilla, J. ( 2013 ) Autologous and allogeneic stem‐cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. Journal of Clinical Oncology, 31, 1 – 9.en_US
dc.identifier.citedreferenceWilliams, C.D., Harrison, C.N., Lister, T.A., Norton, A.J., Blystad, A.K., Coiffier, B., Taghipour, G., Schmitz, N. & Goldstone, A.H. ( 2001 ) High‐dose therapy and autologous stem‐cell support for chemosensitive transformed low‐grade follicular non‐Hodgkin's lymphoma: a case‐matched study from the European Bone Marrow Transplant Registry. Journal of Clinical Oncology, 19, 727 – 735.en_US
dc.identifier.citedreferenceYuen, A.R., Kamel, O.W., Halpern, J. & Horning, S.J. ( 1995 ) Long‐term survival after histologic transformation of low‐grade follicular lymphoma. Journal of Clinical Oncology, 13, 1726 – 1733.en_US
dc.identifier.citedreferenceAl‐Tourah, A.J., Savage, K.J., Gill, K.K., Klasa, R.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. ( 2007 ) Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood (ASH Annual Meeting Abstracts), 110, 790.en_US
dc.identifier.citedreferenceAl‐Tourah, A.J., Gill, K.K., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. ( 2008 ) Population‐based analysis of incidence and outcome of transformed non‐Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 5165 – 5169.en_US
dc.identifier.citedreferenceAndreadis, C., Schuster, S.J., Chong, E.A., Svoboda, J., Luger, S.M., Porter, D.L., Tsai, D.E., Nasta, S.D., Elstrom, R.L., Goldstein, S.C., Downs, L.H., Mangan, P.A., Cunningham, K.A., Hummel, K.A., Gimotty, P.A., Siegel, D.L., Glatstein, E. & Stadtmauer, E.A. ( 2005 ) Long‐term event‐free survivors after high‐dose therapy and autologous stem‐cell transplantation for low‐grade follicular lymphoma. Bone Marrow Transplantation, 36, 955 – 961.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh12570.pdf
Size:
224.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.